The transcriptional modulator BCL6 as a molecular target for breast cancer therapy
MetadataShow full item record
CitationWalker, Sarah R., Suhu Liu, Michael Xiang, Maria Nicolais, Katerina Hatzi, Eugenia Giannopoulou, Olivier Elemento, Leandro Cerchietti, Ari Melnick, and David A. Frank. 2014. “The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.” Oncogene 34 (9): 1073-1082. doi:10.1038/onc.2014.61. http://dx.doi.org/10.1038/onc.2014.61.
AbstractInappropriate expression or activation of transcription factors can drive patterns of gene expression leading to the malignant behavior of breast cancer cells. We have found that the transcriptional repressor BCL6 is highly expressed in breast cancer cell lines, and its locus is amplified in about half of primary breast cancers. To understand how BCL6 regulates gene expression in breast cancer cells, we utilized ChIP-seq to identify the BCL6 binding sites on a genomic scale. This revealed that BCL6 regulates a unique cohort of genes in breast cancer cell lines compared to B cell lymphomas. Furthermore, BCL6 expression promotes the survival of breast cancer cells, and targeting BCL6 with a peptidomimetic inhibitor leads to apoptosis of these cells. Finally, combining a BCL6 inhibitor and a STAT3 inhibitor provided enhanced cell killing in triple negative breast cancer cell lines, suggesting that combination therapy may be particularly useful. Thus, targeting BCL6 alone or in conjunction with other signaling pathways may be a useful therapeutic strategy for treating breast cancer.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:21462162
- HMS Scholarly Articles